Antimicrobial Research Centre (ARC)

Publications (56)

• Article: New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors.

  Ian Chopra
  Drug Resistance Updates 5(3-4):119-25. · 9.56 Impact Factor
• Article: Molecular action of anti-mycobacterial agents.

  I Chopra, P Brennan
  Tubercle and Lung Disease 02/1997; 78(2):89-98.
• Article: N-alkyl-substituted glycopeptide antibiotics.

  I Chopra
  Expert Opinion on Investigational Drugs 04/1997; 6(3):299-303. · 5.27 Impact Factor
• Article: Approaches to antibacterial drug discovery.

  I Chopra
  Expert Opinion on Investigational Drugs 09/1997; 6(8):1019-24. · 5.27 Impact Factor
• Article: Chemotherapy of mycobacterial infections: molecular action of established drugs and investigational agents.

  I Chopra
  Expert Opinion on Investigational Drugs 03/1998; 7(2):253-5. · 5.27 Impact Factor
• Article: Action against antibiotic resistance: no time to lose.

  P M Hawkey
  The Lancet 06/1998; 351(9112):1298-9. · 38.28 Impact Factor
• Source

  Available from: oxfordjournals.org

  Article: Over-expression of target genes as a mechanism of antibiotic resistance in bacteria.

  I Chopra
  Journal of Antimicrobial Chemotherapy 07/1998; 41(6):584-8. · 5.07 Impact Factor
• Article: Protein synthesis as a target for antibacterial drugs: current status and future opportunities.

  I Chopra
  Expert Opinion on Investigational Drugs 09/1998; 7(8):1237-44. · 5.27 Impact Factor
• Source

  Available from: bmj.com

  Article: The origins and molecular basis of antibiotic resistance.

  P M Hawkey
  BMJ 10/1998; 317(7159):657-60. · 14.09 Impact Factor
• Source

  Available from: sgmjournals.org

  Article: Antibiotics, peptidoglycan synthesis and genomics: the chlamydial anomaly revisited.

  I Chopra, C Storey, T J Falla, J H Pearce
  Microbiology 11/1998; 144 ( Pt 10):2673-8. · 3.06 Impact Factor
• Article: Research and development of antibacterial agents.

  I Chopra
  Current Opinion in Microbiology 11/1998; 1(5):495-501. · 7.93 Impact Factor
• Article: Joint tolerance to beta-lactam and fluoroquinolone antibiotics in Escherichia coli results from overexpression of hipA.

  T J Falla, I Chopra
  Antimicrobial Agents and Chemotherapy 01/1999; 42(12):3282-4. · 4.84 Impact Factor
• Source

  Available from: sgmjournals.org

  Article: Stabilization of Rhizobium symbiosis plasmids.

  T J Falla, I Chopra
  Microbiology 04/1999; 145 ( Pt 3):515-6. · 3.06 Impact Factor
• Article: Prospects for antisense agents in the therapy of bacterial infections.

  I Chopra
  Expert Opinion on Investigational Drugs 09/1999; 8(8):1203-8. · 5.27 Impact Factor
• Article: Antimicrobial chemotherapy.

  I Chopra
  IDrugs: the investigational drugs journal 10/1999; 2(9):866-8. · 2.28 Impact Factor
• Source

  Available from: ncbi.nlm.nih.gov

  Article: RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus.

  A O'Neill, B Oliva, C Storey, A Hoyle, C Fishwick, I Chopra
  Antimicrobial Agents and Chemotherapy 12/2000; 44(11):3163-6. · 4.84 Impact Factor
• Source

  Available from: ncbi.nlm.nih.gov

  Article: Affinities of beta-lactams for penicillin binding proteins of Chlamydia trachomatis and their antichlamydial activities.

  C Storey, I Chopra
  Antimicrobial Agents and Chemotherapy 02/2001; 45(1):303-5. · 4.84 Impact Factor
• Article: Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.

  A J O'Neill, J H Cove, I Chopra
  Journal of Antimicrobial Chemotherapy 05/2001; 47(5):647-50. · 5.07 Impact Factor
• Source

  Available from: ncbi.nlm.nih.gov

  Article: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.

  I Chopra, M Roberts
  Microbiology and Molecular Biology Reviews 07/2001; 65(2):232-60 ; second page, table of contents. · 13.02 Impact Factor
• Article: Glycylcyclines: third-generation tetracycline antibiotics.

  I Chopra
  Current Opinion in Pharmacology 11/2001; 1(5):464-9. · 6.86 Impact Factor
• Article: Exploiting current understanding of antibiotic action for discovery of new drugs.

  I Chopra, L Hesse, A J O'Neill
  Symposium series (Society for Applied Microbiology) 02/2002;
• Article: Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes.

  Keith Miller, Alexander John O'Neill, Ian Chopra
  Journal of Antimicrobial Chemotherapy 07/2002; 49(6):925-34. · 5.07 Impact Factor
• Article: Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low.

  Alexander J O'Neill, Ian Chopra
  Journal of Antimicrobial Chemotherapy 08/2002; 50(2):161-9. · 5.07 Impact Factor
• Article: Anti-infectives: the way forward.

  Ian Chopra
  IDrugs: the investigational drugs journal 09/2002; 5(8):800-3. · 2.28 Impact Factor
• Article: Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid.

  A J O'Neill, J M Bostock, A Morais Moita, I Chopra
  Journal of Antimicrobial Chemotherapy 01/2003; 50(6):839-48. · 5.07 Impact Factor
• Article: The role of mutators in the emergence of antibiotic-resistant bacteria.

  Ian Chopra, Alexander J O'Neill, Keith Miller
  Drug Resistance Updates 07/2003; 6(3):137-45. · 9.56 Impact Factor
• Article: Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures.

  Ian Chopra
  Expert Review of Anticancer Therapy 07/2003; 1(1):45-55. · 3.28 Impact Factor
• Article: Functional and biochemical analysis of Chlamydia trachomatis MurC, an enzyme displaying UDP-N-acetylmuramate:amino acid ligase activity.

  Lars Hesse, Julieanne Bostock, Sebastien Dementin, Didier Blanot, Dominique Mengin-Lecreulx, Ian Chopra
  Journal of Bacteriology 12/2003; 185(22):6507-12. · 3.83 Impact Factor
• Source

  Available from: ncbi.nlm.nih.gov

  Article: Escherichia coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections.

  Keith Miller, Alexander John O'Neill, Ian Chopra
  Antimicrobial Agents and Chemotherapy 02/2004; 48(1):23-9. · 4.84 Impact Factor
• Article: The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden.

  Julian G Hurdle, Alex J O'Neill, Ian Chopra
  Journal of Antimicrobial Chemotherapy 02/2004; 53(1):102-4. · 5.07 Impact Factor
• Source

  Available from: ncbi.nlm.nih.gov

  Article: Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.

  A J O'Neill, T Huovinen, C W G Fishwick, I Chopra
  Antimicrobial Agents and Chemotherapy 02/2006; 50(1):298-309. · 4.84 Impact Factor
• Source

  Available from: calstatela.edu

  Article: Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus.

  Alexander John O'Neill, Ian Chopra
  Molecular Microbiology 02/2006; 59(2):664-76. · 5.01 Impact Factor
• Article: The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?

  Ian Chopra
  Journal of Antimicrobial Chemotherapy 05/2007; 59(4):587-90. · 5.07 Impact Factor
• Article: Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus.

  A J O'Neill, A R Larsen, R Skov, A S Henriksen, I Chopra
  Journal of Clinical Microbiology 06/2007; 45(5):1505-10. · 4.15 Impact Factor
• Article: Genetic basis of resistance to fusidic acid in staphylococci.

  A J O'Neill, F McLaws, G Kahlmeter, A S Henriksen, I Chopra
  Antimicrobial Agents and Chemotherapy 06/2007; 51(5):1737-40. · 4.84 Impact Factor
• Article: Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies.

  A A Vickers, A J O'Neill, I Chopra
  Journal of Antimicrobial Chemotherapy 09/2007; 60(2):269-73. · 5.07 Impact Factor
• Article: 2-Aminotetralones: novel inhibitors of MurA and MurZ.

  Colin J Dunsmore, Keith Miller, Katy L Blake, Simon G Patching, Peter J F Henderson, James A Garnett, William J Stubbings, Simon E V Phillips, Deborah J Palestrant, Joseph De Los Angeles, Jennifer A Leeds, Ian Chopra, Colin W G Fishwick
  Bioorganic & medicinal chemistry letters 04/2008; 18(5):1730-4. · 2.65 Impact Factor
• Article: High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis.

  F McLaws, I Chopra, A J O'Neill
  Journal of Antimicrobial Chemotherapy 06/2008; 61(5):1040-3. · 5.07 Impact Factor
• Article: Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center.

  Keith Miller, Colin J Dunsmore, Colin W G Fishwick, Ian Chopra
  Antimicrobial Agents and Chemotherapy 06/2008; 52(5):1737-42. · 4.84 Impact Factor
• Article: Increased mutability of Pseudomonas aeruginosa in biofilms.

  K Driffield, K Miller, J M Bostock, A J O'Neill, I Chopra
  Journal of Antimicrobial Chemotherapy 06/2008; 61(5):1053-6. · 5.07 Impact Factor
• Article: Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.

  Keith Miller, Alexander J O'Neill, Mark H Wilcox, Eileen Ingham, Ian Chopra
  Antimicrobial Agents and Chemotherapy 07/2008; 52(6):1940-4. · 4.84 Impact Factor
• Article: Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.

  Joanne Karen Hobbs, Keith Miller, Alex John O'Neill, Ian Chopra
  Journal of Antimicrobial Chemotherapy 08/2008; 62(5):1003-8. · 5.07 Impact Factor
• Article: Transcriptional signature following inhibition of early-stage cell wall biosynthesis in Staphylococcus aureus.

  A J O'Neill, J A Lindsay, K Gould, J Hinds, I Chopra
  Antimicrobial Agents and Chemotherapy 02/2009; 53(4):1701-4. · 4.84 Impact Factor
• Article: Complete nucleotide sequence of pGO1, the prototype conjugative plasmid from the Staphylococci.

  J A Caryl, A J O'Neill
  Plasmid 04/2009; 62(1):35-8. · 1.52 Impact Factor
• Article: Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques.

  Anna A Vickers, Nicola J Potter, Colin W G Fishwick, Ian Chopra, Alex J O'Neill
  Journal of Antimicrobial Chemotherapy 05/2009; 63(6):1112-7. · 5.07 Impact Factor
• Article: XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity.

  Nicola Ooi, Keith Miller, Joanne Hobbs, William Rhys-Williams, William Love, Ian Chopra
  Journal of Antimicrobial Chemotherapy 09/2009; 64(4):735-40. · 5.07 Impact Factor
• Article: XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms.

  Nicola Ooi, Keith Miller, Christopher Randall, William Rhys-Williams, William Love, Ian Chopra
  Journal of Antimicrobial Chemotherapy 11/2009; 65(1):72-8. · 5.07 Impact Factor
• Article: Structure-based discovery of antibacterial drugs.

  Katie J Simmons, Ian Chopra, Colin W G Fishwick
  Nature Reviews Microbiology 07/2010; 8(7):501-10. · 21.18 Impact Factor
• Article: Staphylococcus aureus SH1000 and 8325-4: comparative genome sequences of key laboratory strains in staphylococcal research.

  A J O'Neill
  Letters in Applied Microbiology 09/2010; 51(3):358-61. · 1.62 Impact Factor
• Article: Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase.

  Katherine R Mariner, Rachel Trowbridge, Anil K Agarwal, Keith Miller, Alex J O'Neill, Colin W G Fishwick, Ian Chopra
  Antimicrobial Agents and Chemotherapy 10/2010; 54(10):4506-9. · 4.84 Impact Factor